ZA201307019B - Compositions for preventing and/or treating and infection by an hiv-1 virus - Google Patents

Compositions for preventing and/or treating and infection by an hiv-1 virus

Info

Publication number
ZA201307019B
ZA201307019B ZA2013/07019A ZA201307019A ZA201307019B ZA 201307019 B ZA201307019 B ZA 201307019B ZA 2013/07019 A ZA2013/07019 A ZA 2013/07019A ZA 201307019 A ZA201307019 A ZA 201307019A ZA 201307019 B ZA201307019 B ZA 201307019B
Authority
ZA
South Africa
Prior art keywords
hiv
virus
infection
compositions
treating
Prior art date
Application number
ZA2013/07019A
Other languages
English (en)
Inventor
Patrice Debre
Vincent Viellard
Original Assignee
Inst Nat Sante Rech Med
Innavirvax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Innavirvax filed Critical Inst Nat Sante Rech Med
Publication of ZA201307019B publication Critical patent/ZA201307019B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
ZA2013/07019A 2011-04-15 2013-09-18 Compositions for preventing and/or treating and infection by an hiv-1 virus ZA201307019B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305451A EP2511295A1 (en) 2011-04-15 2011-04-15 Compositions for preventing and/or treating an infection by an HIV-1 virus
PCT/IB2012/051842 WO2012140620A1 (en) 2011-04-15 2012-04-13 Compositions for preventing and/or treating an infection by an hiv-1 virus

Publications (1)

Publication Number Publication Date
ZA201307019B true ZA201307019B (en) 2014-12-23

Family

ID=44721142

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/07019A ZA201307019B (en) 2011-04-15 2013-09-18 Compositions for preventing and/or treating and infection by an hiv-1 virus

Country Status (11)

Country Link
US (3) US9181299B2 (cg-RX-API-DMAC10.html)
EP (2) EP2511295A1 (cg-RX-API-DMAC10.html)
JP (1) JP6027094B2 (cg-RX-API-DMAC10.html)
CN (1) CN103687875B (cg-RX-API-DMAC10.html)
BR (1) BR112013026150B1 (cg-RX-API-DMAC10.html)
CA (1) CA2831258C (cg-RX-API-DMAC10.html)
ES (1) ES2912099T3 (cg-RX-API-DMAC10.html)
RU (1) RU2603262C2 (cg-RX-API-DMAC10.html)
UA (1) UA112863C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012140620A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201307019B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
BR112019021787A2 (pt) * 2017-04-18 2020-05-05 Inst Pathogen Biology Cams lipopeptídeo para inibição potente do hiv, seu derivado, composição farmacêutica e uso do mesmo
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU2002251058A1 (en) * 2001-02-16 2002-09-04 Hybrigenics Protein-protein interactions in saccharomyces cerevisiae
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2009026353A1 (en) * 2007-08-20 2009-02-26 New York University Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies
CN104232679A (zh) * 2009-01-28 2014-12-24 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物及其制备方法
AP3402A (en) * 2009-02-06 2015-08-31 Mymetics Corp Splitting GP41
WO2011005289A2 (en) * 2009-06-23 2011-01-13 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity

Also Published As

Publication number Publication date
US9181299B2 (en) 2015-11-10
ES2912099T3 (es) 2022-05-24
WO2012140620A1 (en) 2012-10-18
US9802983B2 (en) 2017-10-31
WO2012140620A8 (en) 2013-11-07
CN103687875B (zh) 2016-10-19
RU2603262C2 (ru) 2016-11-27
JP6027094B2 (ja) 2016-11-16
BR112013026150A2 (pt) 2016-09-06
EP2697259A1 (en) 2014-02-19
US20180057535A1 (en) 2018-03-01
EP2511295A1 (en) 2012-10-17
EP2697259B1 (en) 2022-02-09
CA2831258A1 (en) 2012-10-18
JP2014512367A (ja) 2014-05-22
US20140037666A1 (en) 2014-02-06
US20160031943A1 (en) 2016-02-04
CN103687875A (zh) 2014-03-26
US10174080B2 (en) 2019-01-08
UA112863C2 (uk) 2016-11-10
CA2831258C (en) 2020-07-14
BR112013026150B1 (pt) 2022-08-09
RU2013145467A (ru) 2015-05-20

Similar Documents

Publication Publication Date Title
IL273194A (en) Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
EP2764102A4 (en) METHOD AND COMPOSITIONS FOR REGULATING HIV INFECTIONS
IL245348A0 (en) Compounds for the treatment of paramyxoviridae virus infections
SG11201500439RA (en) Vaccine compositions for prevention against dengue virus infection
IL229902B (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
WO2014052836A3 (en) Methods and compositions for treating infection
GB201213087D0 (en) Inhibition of HIV-1 infection
ZA201404494B (en) Method for treating hepatitis c virus infection using quercetin-containing compositions
ZA201205547B (en) Therapies for treating hepatitis c virus infection
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
PL2534150T3 (pl) Sposoby leczenia infekcji wirusowej
IL230487A0 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
SG11201502221WA (en) Novel attenuated dengue virus strains for vaccine application
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
IL236476A0 (en) Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it
EP2624841A4 (en) COMPOSITIONS FOR TREATING CHRONIC VIRAL INFECTIONS
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
IL221399A (en) Composition for the treatment of viral diseases
PT2838903T (pt) Métodos e composições para tratamento de infeções virais
SG11201402899TA (en) Methods and compositions for treating viral diseases
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
EP2826486A4 (en) PRODUCT FOR TREATING VIRAL HEPATITIS C